Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options

Tumor Biology

Volumn 37, Issue 9, 2016, Pages 11691-11700

  Grech, Godfrey ^a   Baldacchino, Shawn ^a   Saliba, Christian ^a   Grixti, Maria Pia ^a   Gauci, Robert ^a   Petroni, Vanessa ^a   Fenech, Anthony G ^a   Scerri, Christian ^a,b  

^a UNIVERSITY OF MALTA   (Malta)

^b MATER DEI HOSPITAL   (Malta)

Author keywords

Breast cancer; Colorectal cancer; Kinase inhibitors; Molecular targets; Novel therapeutics; Phosphatase activation; PP2A complex

Indexed keywords

BORTEZOMIB; CARNOSIC ACID; FINGOLIMOD; FORSKOLIN; METHYLPREDNISOLONE; NUCLEAR PROTEIN; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2AA; PHOSPHOPROTEIN PHOSPHATASE 2AB; PHOSPHOPROTEIN PHOSPHATASE 2AC; PHOSPHOPROTEIN PHOSPHATASE 2R5A; PROTEIN CIP2A; PROTEIN IGBP1; PROTEIN SET; REGULATOR PROTEIN; SET BINDING PROTEIN 1; UNCLASSIFIED DRUG; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN SUBUNIT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CATALYSIS; CHEMICAL MODIFICATION; COLORECTAL CANCER; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; METHYLATION; NEOPLASM; PRIORITY JOURNAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME ACTIVATION; ENZYMOLOGY; NEOPLASMS; PHYSIOLOGY; PROTEIN SUBUNIT;

ANIMALS; ENZYME ACTIVATION; HUMANS; NEOPLASMS; PROTEIN PHOSPHATASE 2; PROTEIN SUBUNITS;

EID: 84979272574     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5145-4     Document Type: Review

References (91)

1. Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzym Res. 2012;2012:1–11.
2. Qi Z, Yang W, Liu Y, Cui T, Gao H, et al. Loss of PINK1 function decreases PP2A activity and promotes autophagy in dopaminergic cells and a murine model. Neurochem Int. 2011;59:572–81.
3. Kloeker S, Reed R, McConnell JL, Chang D, Tran K, et al. Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2AC, PP4C, and PP6C) and analysis of the interaction of PP2AC with alpha4 protein. Protein Expr Purif. 2003;31:19–33.
4. Silverstein AM. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci. 2002;99:4221–6.
5. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53–62.
6. Sablina A, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010;70:10474–84.
7. Hahn K, Miranda M, Francis VA, Vendrell J, Zorzano A, et al. PP2A regulatory subunit PP2A-B′ counteracts S6K phosphorylation. Cell Metab. 2010;11:438–44.
8. Margolis SS, Perry JA, Forester CM, Nutt LK, Guo Y, et al. Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell. 2006;127:759–73.
9. Alvarez-Fernandez M, Halim VA, Aprelia M, Mohammed S, Medema RH. Protein phosphatase 2A (B55) prevents premature activation of forkhead transcription factor FoxM1 by antagonizing cyclin A/cyclin-dependent kinase-mediated phosphorylation. J Biol Chem. 2011;286:33029–36.
10. Jin Z, Wallace L, Harper SQ, Yang J. PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development. J Biol Chem. 2010;285:34493–502.
11. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541–51.
12. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, et al. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 2009;69:2870–7.
13. Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, et al. (2013) The regulatory roles of phosphatases in cancer. Oncogene.
14. Ismail HMS, Myronova O, Tsuchiya Y, Niewiarowski A, Tsaneva I, et al. Identification of the general transcription factor Yin Yang 1 as a novel and specific binding partner for S6 kinase 2. Cell Signal. 2013;25:1054–63.
15. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130:21–4.
16. Baldacchino S, Saliba C, Petroni V, Fenech AG, Borg N, et al. Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. EPMA J. 2014;5:3.
17. Cristobal I, Manso R, Rincon R, Carames C, Senin C, et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther. 2014;13:938–47.
18. Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013;335:9–18.
19. Ruediger R, Hentz M, Fait J, Mumby M, Walter G. Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigens. J Virol. 1994;68:123–9.
20. Hemmings BA, Adams-Pearson C, Maurer F, Mueller P, Goris J, et al. Alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry. 1990;29:3166–73.
21. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005;15:34–41.
22. Gu P, Qi X, Zhou Y, Wang Y, Gao X. Generation of Ppp2Ca and Ppp2Cb conditional null alleles in mouse. Genesis. 2012;50:429–36.
23. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science. 1992;257:1261–4.
24. Sontag J-M, Nunbhakdi-Craig V, Mitterhuber M, Ogris E, Sontag E. Regulation of protein phosphatase 2A methylation by LCMT1 and PME-1 plays a critical role in differentiation of neuroblastoma cells. J Neurochem. 2010;115:1455–65.
25. Sents W, Ivanova E, Lambrecht C, Haesen D, Janssens V. The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity. FEBS J. 2013;280:644–61.
26. Stanevich V, Jiang L, Satyshur KA, Li Y, Jeffrey PD, et al. The structural basis for tight control of PP2A methylation and function by LCMT-1. Mol Cell. 2011;41:331–42.
27. (2013) GeneCards—The human gene compendium.
28. Gray KA, Daugherty LC, Gordon SM, Seal RL, Wright MW, et al. Genenames.org: the HGNC resources in 2013. Nucleic Acids Res. 2013:41.
29. Laine A. The role of an oncoprotein cip2a in breast carcinoma. Turku: University of Turku; 2013.
30. Kong M, Fox CJ, Mu J, Solt L, Xu A, et al. The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science. 2004;306:695–8.
31. Slupe AM, Merrill RA, Strack S. Determinants for substrate specificity of protein phosphatase 2A. Enzym Res. 2011;2011:1–8.
32. Xu Y, Xing Y, Chen Y, Chao Y, Lin Z, et al. Structure of the protein phosphatase 2A holoenzyme. Cell. 2006;127:1239–51.
33. Yu XX, Du X, Moreno CS, Green RE, Ogris E, et al. Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen. Mol Biol Cell. 2001;12:185–99.
34. Jackson JB, Pallas DC. Circumventing cellular control of PP2A by methylation promotes transformation in an Akt-dependent manner. Neoplasia. 2012;14:585–99.
35. Calin GA, Iasio MG, Caprini E, Vorechovsky I, Natali PG, et al. Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene. 2000;19:1191–5.
36. Ruediger R, Ruiz J, Walter G. Human cancer-associated mutations in the A α subunit of protein phosphatase 2A increase lung cancer incidence in A α knock-in and knockout mice. Mol Cell Biol. 2011;31:3832–44.
37. Wang SS, Esplin ED, Li JL, Huang L, Evans GA. Alterations of the PPP2R1B gene in human lung and colon cancer. Science. 1998;282:284–7.
38. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, et al. Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut. 2000;47:268–71.
39. Chou H-C, Chen C-H, Lee H-S, Lee C-Z, Huang G-T, et al. Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma. Cancer Lett. 2007;253:138–43.
40. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, et al. The tumor suppressor PP2A Aβ regulates the RalA GTPase. Cell. 2007;129:969–82.
41. Cheng Y, Liu W, Kim S-T, Sun J, Lu L, et al. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet. 2011;204:375–81.
42. Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene. 2012;31:4266–78.
43. Migueleti DLS, Smetana JHC, Nunes HF, Kobarg J, Zanchin NIT. Identification and characterization of an alternatively spliced isoform of the human protein phosphatase 2A catalytic subunit. J Biol Chem. 2011;287:4853–62.
44. Grech G, Blazquez-Domingo M, Kolbus A, Bakker WJ, Mullner EW, et al. Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation. Blood. 2008;112:2750–60.
45. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355–68.
46. Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, et al. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway. Oncogene. 2009;29:739–51.
47. O’Hare T, Deininger MWN, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2010;17:212–21.
48. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, et al. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;117:6660–8.
49. Barjesteh van Waalwijk van Doorn-Khosrovani S, Spensberger D, de Knegt Y, Tang M, Lowenberg B, et al. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene. 2005;24:4129–37.
50. Minakuchi M, Kakazu N, Gorrin-Rivas MJ, Abe T, Copeland TD, et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem. 2001;268:1340–51.
51. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.
52. Vaarala MH, Väisänen M-R, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.
53. Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer. 2011;105:989–95.
54. Teng H-W, Yang S-H, Lin J-K, Chen W-S, Lin T-C, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 2012;16:1037–47.
55. Come C, Laine A, Chanrion M, Edgren H, Mattila E, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092–100.
56. Wang J, Li W, Li L, Yu X, Jia J, et al. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol. 2011;33:290–8.
57. Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, et al. PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. 2011;31:1484–92.
58. Lazar DF, Saltiel AR. Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov. 2006;5:333–42.
59. Lyon MA, Ducruet AP, Wipf P, Lazo JS. Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov. 2002;1:961–76.
60. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7:833–46.
61. Liu J, Farmer Jr JD, Lane WS, Friedman J, Weissman I, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807–15.
62. Bachovchin DA, Zuhl AM, Speers AE, Wolfe MR, Weerapana E, et al. Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. J Med Chem. 2011;54:5229–36.
63. Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, et al. Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc Natl Acad Sci U S A. 2011;108:6811–6.
64. Pusey M, Bail S, Xu Y, Buiakova O, Nestor M, et al. (2016) Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models. Tumour Biol.
65. Madhunapantula SV, Robertson GP. Therapeutic implications of targeting AKT signaling in melanoma. Enzyme Res. 2011;2011:327923.
66. Hwang YY, Liang RH. An update in management of noncutaneous T-cell lymphomas. Adv Hematol. 2010;2010:424786.
67. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol. 2011;186:2535–42.
68. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117:2408–21.
69. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005;108:308–19.
70. Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, et al. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia. 2014;28:1915–8.
71. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, et al. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011;25:606–14.
72. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003;169:2372–7.
73. Zhang N, Qi Y, Wadham C, Wang L, Warren A, et al. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy. 2010;6:1157–67.
74. Zheng T, Meng X, Wang J, Chen X, Yin D, et al. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem. 2010;111:218–28.
75. Dumont AG, Reynoso DG, Trent JC. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers—letter. Cancer Res. 2011;71:2403.author reply 2404
76. Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology. 2011;53:1943–58.
77. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 2009;23:751–63.
78. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, et al. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011;30:2504–13.
79. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, et al. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 2012;14:R68.
80. Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, et al. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis. 2014;35:905–14.
81. Liu Z, Ma L, Wen ZS, Cheng YX, Zhou GB. Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells. ACS Med Chem Lett. 2014;5:113–8.
82. Uzunoglu S, Uslu R, Tobu M, Saydam G, Terzioglu E, et al. Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. Leuk Res. 1999;23:507–12.
83. Liao Y, Hung MC. A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. Cancer Res. 2004;64:5938–42.
84. Switzer CH, Glynn SA, Ridnour LA, Cheng RY, Vitek MP, et al. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci. 2011;32:644–51.
85. Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 2002;16:706–8.
86. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev. 2008;27:159–68.
87. Switzer CH, Ridnour LA, Cheng RY, Sparatore A, Del Soldato P, et al. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene. 2009;28:3837–46.
88. Kar S, Palit S, Ball WB, Das PK. Carnosic acid modulates Akt/IKK/NF-kappaB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis. 2012;17:735–47.
89. McClinch K, Avelar R, Callejas D, Kastrinsky D, Ohlmeyer M, Plymate S, et al. Therapeutic reactivation of PP2A for prostate cancer treatment; 2015 Nov 5–9; Boston, MA. Philadelphia (PA): Molecular targets and cancer therapeutics.
90. Naetar N, Soundarapandian V, Litovchick L, Goguen KL, Sablina AA, et al. PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Mol Cell. 2014;54:932–45.
91. Hong CS, Ho W, Zhang C, Yang C, Elder JB, et al. LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol Ther. 2015;16:821–33.